Efficacy and Safety of Anti-nerve Growth Factor Monoclonal Antibodies in Managing Chronic Musculoskeletal Pain: A Systematic Review with Network Meta-analysis - PubMed
5 hours ago
- #anti-NGF monoclonal antibodies
- #network meta-analysis
- #chronic musculoskeletal pain
- Anti-NGF mAbs like fasinumab and tanezumab show the highest efficacy in reducing pain and improving function in chronic musculoskeletal pain compared to placebo.
- Fasinumab and tanezumab are associated with significantly increased risks of adverse events, including adjudicated arthropathies and abnormal peripheral sensation.
- Fulranumab is less effective than fasinumab and tanezumab but has a better overall safety profile, with only a significant risk for abnormal peripheral sensation.
- The systematic review and network meta-analysis included 29 studies with 27,747 patients, focusing on osteoarthritis and chronic low back pain.
- Strict safety protocols are recommended when considering anti-NGF mAbs for further evaluation due to their efficacy-safety trade-off.